What is GT Biopharma Financial Strength?
GT Biopharma has the Financial Strength Rank of 7.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:
1. The debt burden that the company has as measured by its
Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3.
Altman Z-Score.
GT Biopharma has no long-term debt (1).
As of today, GT Biopharma's Altman Z-Score is 0.00.
(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Competitive Comparison of GT Biopharma's Financial Strength
For the Biotechnology subindustry, GT Biopharma's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GT Biopharma's Financial Strength Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, GT Biopharma's Financial Strength distribution charts can be found below:
* The bar in red indicates where GT Biopharma's Financial Strength falls into.
GT Biopharma Financial Strength Calculation
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
GT Biopharma's Interest Expense for the
months ended in Mar. 2024 was $0.00 Mil. Its Operating Income for the
months ended in Mar. 2024 was $-3.09 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.00 Mil.
GT Biopharma's Interest Coverage for the quarter that ended in Mar. 2024 is
| GT Biopharma had no long-term debt (1). |
The higher the ratio, the stronger the company's financial strength is.
2. Debt to revenue ratio. The lower, the better.
GT Biopharma's Debt to Revenue Ratio for the quarter that ended in Mar. 2024 is
3. Altman Z-Score.
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
GT Biopharma has a Z-score of 0.00, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GT Biopharma (GT Biopharma) Business Description
Traded in Other Exchanges
Address
8000 Marina Boulevard, Suite 100, Brisbane, CA, USA, 94005
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.
Executives
| Charles J Casamento |
director |
99 BELBROOK WAY, ATHERTON CA 94027 |
| Michael Martin Breen |
director, officer: Exec. Chair. and Interim CEO |
LOWSLEY HOUSE 133 HEADLEY ROAD, LIPHOOK X0 GU30 7PU |
| Manu Ohri |
officer: CFO & Secretary |
2355 MAIN STREET, SUITE 120, IRVINE CA 92614 |
| Bruce Wendel |
director |
70 ELEVEN O'CLOCK ROAD, WESTON CT 06883 |
| Gregory Berk |
officer: Pres. of R&D, CMO |
HANA BIOSCIENCES, INC., 400 OYSTER POINT BLVD, SAN FRANCISCO CA 94080 |
| Shrotriya Rajesh C Md |
director |
157 TECHNOLOGY DRIVE, IRVINE CA 92618 |
| Alan Louis Urban |
director |
1524 CLOVERFIELD BOULEVARD, SUITE E, SANTA MONICA CA 90404 |
| Gavin Choy |
officer: Acting Chief Financial Officer |
8000 MARINA BLVD, STE. 100, C/O GT BIOPHARMA, INC., BRISBANE CA 94005 |
| Steven W Weldon |
director, officer: CFO |
7280 WESTPOINTE BLVD, APT 831, ORLANDO FL 32835 |
| Shawn Cross |
director, officer: Chief Executive Officer |
1825 K STREET SUITE 510, WASHINGTON DC 20006 |
| Raymond W. Urbanski |
officer: Chief Medical Officer |
28903 NORTH AVENUE PAINE, VALENCIA CA 91355 |
| Kathleen Clarence-smith |
director, 10 percent owner, officer: CEO |
1623 31ST STREET NW, WASHINGTON DC 20007 |
| Mark J Silverman |
10 percent owner |
224 22ND ST., SANTA MONICA CA 90402 |
| Bristol Capital Llc |
10 percent owner |
|
| Bristol Investment Fund Ltd |
10 percent owner |
89 NEXUS WAY, CAMANA BAY, PO BOX 311063, GRAND CAYMAN E9 KY1-1205 |
GT Biopharma (GT Biopharma) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
GTBP has been successfully added to your